Degludec insulin

Phase 3Small molecule

Sunshine Lake Pharma Co., Ltd.

Degludec insulin is one of 56 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusEnrolling by invitation

Critically Ill PatientsCompleted

Diabetes MellitusPhase 3

Enrolling by invitation

Critically Ill PatientsPreclinical

Completed

Competition

Competitive Landscape

111 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

7 2

Actos

Takeda

Approved

3 3

Plavix

Sanofi

Approved

3 4

Jardiance

Boehringer Ingelheim

Approved

13 5

Geodon

Pfizer

Approved

1 6

Tradjenta

Boehringer Ingelheim

Approved

5 7

Januvia

ZZydus Therapeutics Inc.

Approved

5 8

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

3 9

Topamax

WWim Janssens

Approved

—10

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Study completion

NCT07376200

Clinical

Trials by Indication[1]

Critically Ill Patients1 trial

Degludec Insulin Use in Critically Ill Patients

Completed·KKing Faisal Specialist Hospital & Research Center·N/A·NCT06056167·155 enrolled

Diabetes Mellitus1 trial

A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus

Enrolling by invitation·—·Phase 4·NCT06925334·170 enrolled

Unspecified1 trial

An I-phase Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics of a Single Dose of HEC-151 Injection in Healthy Chinese Participants in a Single-center, Randomized, Placebo (Single-blind) and Positive Control (Open-label) Study

Recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 1·NCT07376200·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Degludec insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Degludec insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Degludec insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Lake Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sunshine Lake Pharma Co., Ltd.

Degludec insulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Critically Ill Patients1 trial

Diabetes Mellitus1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News